COVID-19 Funding Opportunities
The Office of the Vice Provost for Research (VPR) has compiled a list of funding opportunities specific to COVID-19. This list will be updated as new opportunities arise.
Internal deadline: August
The Robert J. Kleberg,
Jr. and Helen C. Kleberg Foundation is seeking highly innovative and
groundbreaking medical research proposals in both basic biological and
applied research that will have the greatest impact on scientific knowledge
and human health. The Foundation focuses on basic science and some translational
- not clinical research. Proposals should be distinctive and novel in
their approaches, question the prevailing paradigm, and lead to advancement
of knowledge in the field. A highly qualified scientific advisory committee
will review all proposals.
Applicants must be
faculty-eligible to serve as a Principal Investigator. Johns Hopkins
may submit one nominee for this $1,000,000 award.
should complete their application at the following link: https://jhu.infoready4.com/#competitionDetail/1846602.
Requirements are listed
Questions? Comments? Email the Office of Foundation
Relations at FoundationRelations@jhu.edu.
Internal deadline: August 19, 2021
The Greenwall Faculty Scholars Program in Bioethics
is a career development award to enable junior faculty members to carry
out innovative bioethics research. It supports research that goes beyond
current work in bioethics to help resolve pressing ethical issues in
clinical, biomedical, and public health decision-making,
policy, and practice, and creates a community that enhances future bioethics
research by Scholars and Alumni/ae.
Internal Nomination Process:
Requirements are listed below.
Questions? Comments? Email the Office of
Foundation Relations at FoundationRelations@jhu.edu.
Internal deadline: September 7, 2021
This announcement encourages Collaborative Program
Grant applications that propose to conduct research to address complex
and challenging biomedical problems, important for the mission
of the National Institute of General Medical Sciences (NIGMS), through
deeply integrated, multidisciplinary research teams. The Grant is designed
to support research in which funding a team of interdependent investigators
offers significant advantages over support of individual research project
grants. Applications should address critical issues and be sufficiently
challenging, ambitious, and innovative that objectives could not be
achieved by individual investigators. Applications may address any area
of science within the NIGMS mission, which is to support basic research
that increases understanding of biological processes at a range of levels,
from molecules and cells to tissues, whole organisms and populations.
Eligibility & Requirements:
Consultation with relevant staff at least 10 weeks
prior to the application due date is strongly encouraged.
Internal Nomination Process:
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use.